https://www.a7iintelligence.com/wire/ Verified developments in Gulf biotechnology. en-AU 2026-10-18 https://www.a7iintelligence.com/wire/#wire-068 https://www.a7iintelligence.com/wire/#wire-068 The Global Health Exhibition will return on 25 to 28 October 2027 under the theme Invest in Health, its organiser announced, rescheduling the ninth edition that the Ministry of Health had set for 26 to 29 October 2026 at the Riyadh Exhibition and Convention Center (Malham). The organiser says the new dates allow more time to build international participation, partnerships and investment. A Global Health Exhibition Digital Forum runs from 26 October to 20 December 2026, with 30 industry webinars, 15 leadership interviews and a healthcare market report. Why it matters. The exhibition is one of the Kingdom's main health-sector deal venues, reporting USD 35.5bn in deals at its 2025 edition, and the 2026 plan anticipated more than 130,000 healthcare professionals, 2,200 brands and 1,000 investors from over 100 countries. Fixed 2027 dates give exhibitors and investors a clear planning horizon. Opportunity Saudi Arabia 2026-10-18 https://www.a7iintelligence.com/wire/#wire-069 https://www.a7iintelligence.com/wire/#wire-069 Dr Nerissa Naidoo, Associate Professor of Anatomy at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), is studying whether the epigenetic changes that drive cartilage breakdown, inflammation and cellular stress can be modified to slow, stop or potentially reverse osteoarthritis. The work uses patient-derived cartilage cells from osteoarthritic knee and hip tissue to test pharmaceutical and nutraceutical interventions. It is funded by the Dubai Research, Development and Innovation Grant Initiative under the Dubai Future Foundation, with clinical collaboration from King's College Hospital London Dubai and teams at MBRU and Rashid Hospital. Why it matters. The programme aims at disease-modifying therapy for a condition that affects more than 500 million people worldwide. It also shows Dubai's research grant scheme seeding translational precision medicine inside a local medical university. Science UAE 2026-10-17 https://www.a7iintelligence.com/wire/#wire-070 https://www.a7iintelligence.com/wire/#wire-070 Pierre Fabre Laboratories has inaugurated a hub near Dubai Marina as the headquarters of its Middle East, Africa, Russia and Turkey subsidiary. The company operates directly in 44 countries and has been present in the region since the 1980s, with a medical portfolio in oncology, dermatology and rare diseases alongside dermo-cosmetic brands including Avène, Ducray and A-Derma. Chief executive Eric Ducournau linked the hub to the group's plan to lift revenue from €3.1bn in 2024 to at least €5bn by 2032. Why it matters. A regional headquarters places commercial leadership for oncology, dermatology and rare-disease medicines in Dubai, confirming the emirate as the management base for multinational pharma across a wide emerging-market footprint. Company UAE 2026-10-15 https://www.a7iintelligence.com/wire/#wire-071 https://www.a7iintelligence.com/wire/#wire-071 KAUST says two biomedical microgravity experiments using brain cells, SSA-1 and SSA-2, are heading to the International Space Station on the SpaceX CR35 flight under the Saudi Space Agency's BioGravity Program, with Axiom Space and California's National Stem Cell Foundation as partners. Professor Imed Gallouzi leads the work, which targets Alzheimer's disease and multiple sclerosis, with Rayyanah Barnawi, the first Saudi woman astronaut and now a KAUST PhD candidate, and research scientist Dr Andrea Diaz Gaxiola, who prepared the precursor cells developed into brain cell types and organoids. The experiments set a baseline, and later missions are planned to use patient-derived samples to study disease progression and treatment responses. Why it matters. The project connects the Kingdom's space and life-sciences programmes in a repeatable research pathway, with KAUST, the Saudi Space Agency and commercial spaceflight partners each playing a role. Science Saudi Arabia 2026-10-14 https://www.a7iintelligence.com/wire/#wire-072 https://www.a7iintelligence.com/wire/#wire-072 SFDA Chief Executive Dr Hisham S. Aljadhey met chief executives and representatives of food companies at the authority's Riyadh headquarters on 13 October. He said the sector's performance indicators are improving across the Kingdom and that artificial intelligence is strengthening risk prediction, so preventive action can be taken before problems arise. Business leaders put forward proposals on upcoming priorities to inform the SFDA's next strategic framework. Why it matters. The SFDA is drawing on industry input for its next strategy and putting AI-led risk prediction at the centre of food oversight, setting the direction for how food products will be regulated in the Kingdom. Regulation Saudi Arabia 2026-10-13 https://www.a7iintelligence.com/wire/#wire-053 https://www.a7iintelligence.com/wire/#wire-053 The Abu Dhabi Public Health Centre has introduced a nasal spray influenza vaccine for the first time for the 2026 to 2027 season, Gulf News reported on 12 October. It sits alongside standard injections for eligible people aged six months and above and a high-dose vaccine for those aged 65 and above, all free for eligible residents across Abu Dhabi, Al Ain and Al Dhafra. About 350,000 people were vaccinated in the emirate during the 2025 to 2026 season through 130 healthcare facilities and 11 outpatient pharmacies. Why it matters. Offering three formats matched to age and health status moves the programme toward product-level choice. A needle-free option gives families a further route to vaccinating children, one of the season's priority groups. Clinical UAE 2026-10-12 https://www.a7iintelligence.com/wire/#wire-052 https://www.a7iintelligence.com/wire/#wire-052 The Abu Dhabi Public Health Centre (ADPHC) announced on 12 October a memorandum of understanding with Ultrahuman Healthcare to develop and validate a Biological Health Age model. The model combines clinical biomarker data with wearable health data to show how cardiovascular health, sleep, metabolism and recovery shape long-term health. The two-year agreement covers joint scientific research, clinical validation and responsible use of health data, with all data kept within the emirate under clinical oversight. Why it matters. A validated biological age measure gives Abu Dhabi a population-scale endpoint for prevention, the unit in which longevity interventions will increasingly be judged. Keeping the data in the emirate under clinical governance positions the model as a public-health asset rather than a consumer metric. Partnership UAE 2026-10-12 https://www.a7iintelligence.com/wire/#wire-073 https://www.a7iintelligence.com/wire/#wire-073 Omani pharmaceutical companies signed four agreements at the Oman Pavilion at CPHI Worldwide 2026 in Milan, in a delegation led by the Public Authority for Special Economic Zones and Free Zones. Dhofar Pharmaceutical Industries and Iraq's Hydrogen Oncology Pharmaceuticals agreed to build a plant at Raysut Industrial City to manufacture cancer medicines locally, and Dhofar Pharmaceutical Industries signed an industrial cooperation memorandum with Felix Pharmaceutical Industries. Jordan's Sana Pharma and Oman's National Pharmaceutical Industries agreed to exchange drug dossiers and transfer technology, and manufacturing technology for an Omani diabetes medicine will be transferred to Algeria. Oman took part with eight national pharmaceutical factories, and its pharmaceutical and medical product exports reached about $68.9m (OMR26.5m) in 2025. Why it matters. A local oncology plant moves Oman into a high-value therapeutic category, and the Algeria transfer shows Omani manufacturing know-how becoming an export in its own right. Both advance Oman Vision 2040's goals on medicine security and industrial diversification. Manufacturing Oman 2026-10-10 https://www.a7iintelligence.com/wire/#wire-054 https://www.a7iintelligence.com/wire/#wire-054 Avalon Pharma signed an exclusive licensing agreement with India-based OneSource Specialty Pharma on 8 October for a generic version of the Mounjaro KwikPen, a tirzepatide multi-dose pen in strengths from 2.5 mg to 15 mg. Avalon will hold the marketing authorisation and the exclusive rights to register and market the product in Saudi Arabia and other MENA markets, for a term of 10 years from launch that renews automatically each year. The company expects cumulative revenue of at least SAR 800 million in the first five years after launch, with rollout in each market following patent expiry, and may request a manufacturing technology transfer once the product has launched. Why it matters. The agreement gives a Saudi manufacturer exclusive regional rights in incretin-based metabolic therapy ahead of generic entry. The technology transfer option sets out a path from importing the pen to producing it in the Kingdom. Partnership Saudi Arabia 2026-10-08 https://www.a7iintelligence.com/wire/#wire-075 https://www.a7iintelligence.com/wire/#wire-075 Bahrain's Ministry of Industry and Commerce presented the Kingdom's investment opportunities at the first Made in GCC 2026 Forum and Exhibition, which closed on 7 October at Exhibition World Bahrain. Target sectors included pharmaceuticals, with imports of BD76.4m, and laboratory equipment, alongside food, aircraft components and smart devices. The forum, opened by Crown Prince and Prime Minister Prince Salman bin Hamad Al Khalifa on behalf of the King, drew more than 10,500 visitors and more than 120 companies. Why it matters. Putting a figure on the pharmaceutical import bill gives investors a sized, ready market for locally produced medicines. Pairing it with laboratory equipment points to an adjacent life-sciences supply chain the ministry wants built at home. Opportunity Bahrain 2026-10-07 https://www.a7iintelligence.com/wire/#wire-074 https://www.a7iintelligence.com/wire/#wire-074 Hamad Medical Corporation's Department of Laboratory Medicine and Pathology launched a new phase of its Human Tissue Biobank with the Qatar Precision Health Institute on 7 October. Phase one holds at least 700,000 paraffin blocks and 2.6 million tissue slides, including at least 250,000 immunohistochemistry slides, and has supported at least 58 research applications. The new phase stores freshly removed tissue through two pathways: a clinical pathway for molecular and genomic testing, next-generation sequencing and precision oncology, and a research pathway offered as a national platform under Medical Research Center ethical review. Why it matters. Fresh tissue is the raw material for sequencing-led diagnosis and biomarker discovery. Linking Hamad's pathology service with QPHI turns a large archival collection into active precision medicine infrastructure. Infrastructure Qatar 2026-10-07 https://www.a7iintelligence.com/wire/#wire-059 https://www.a7iintelligence.com/wire/#wire-059 NYU Abu Dhabi's Ramadi Lab reported on 7 October two stent designs for draining abscesses caused by leaks after bariatric surgery, a clinical problem raised by clinicians at Cleveland Clinic Abu Dhabi. The Lily stent uses a six-part, flower-like cross-section to improve flow, and BRIDGE is 3D-printed with an internal lattice that bends through complex anatomy without kinking. In laboratory testing BRIDGE more than doubled drainage performance against conventional stents, and the team is developing biodegradable materials so the device breaks down once the leak heals. Why it matters. This is clinician-led device engineering inside the UAE, with the problem defined at the bedside and the prototype built in an Abu Dhabi lab. A stent that dissolves after healing would spare patients a second procedure. Science UAE 2026-10-07 https://www.a7iintelligence.com/wire/#wire-058 https://www.a7iintelligence.com/wire/#wire-058 World Health Expo, with Frost & Sullivan, released From Discovery to Delivery: The Technologies Reshaping Global Biopharma in Dubai on 7 October. The report projects precision medicine in the Middle East to grow 10 to 12% over the next five to seven years, a trajectory similar to developed markets, and values the Middle East and Africa pharmaceutical market at US$58.66bn in 2025. It cites the Emirati Genome Program's goal of one million samples, a UAE Reference Genome study analysing more than 50,000 genomes, and Abu Dhabi's HELM cluster, projected to attract over AED42bn in investment by 2045. Why it matters. An independent market forecast anchored on UAE genomics infrastructure gives investors a reference range for the region's precision-medicine thesis. It also shows population genome programmes being read as commercial assets as well as public-health ones. Opportunity UAE 2026-10-07 https://www.a7iintelligence.com/wire/#wire-057 https://www.a7iintelligence.com/wire/#wire-057 Tadawul-listed Avalon Pharma signed a memorandum of understanding with China-based Aurisco Pharma to explore cooperation in oligonucleotide and other complex pharmaceutical products, starting with inclisiran. The cooperation is designed to grow into a broader platform covering pharmaceutical development, technology transfer and local manufacturing in Saudi Arabia. Aurisco specialises in manufacturing oligonucleotide active pharmaceutical ingredients, formulation process and analytical method development, and technology transfer. Why it matters. Oligonucleotides act on disease at the RNA level and depend on specialised synthesis expertise. Partnering with an API specialist gives Avalon a structured route to bring this modality into the Kingdom. Partnership Saudi Arabia 2026-10-07 https://www.a7iintelligence.com/wire/#wire-056 https://www.a7iintelligence.com/wire/#wire-056 On 7 October the SFDA granted Breakthrough Medicine designation to Roche's Wilsirdli (giredestrant), at the company's request, for adjuvant treatment of early ER+/HER2- breast cancer and, in combination with everolimus, locally advanced or metastatic disease. On 1 October it granted the same designation to Sanofi's Infilbray (venglustat) for long-term treatment of type 3 Gaucher disease in patients aged two years and older. Both medicines can now be submitted and reviewed under the Breakthrough Track, which shortens regulatory timelines and allows earlier patient access, with registration decided after full evaluation of each dossier. Why it matters. The programme gives sponsors who file in Saudi Arabia early a faster review. Two designations in one week, one in oncology and one in a rare genetic disorder, show multinational sponsors actively using the track. Regulation Saudi Arabia 2026-10-07 https://www.a7iintelligence.com/wire/#wire-055 https://www.a7iintelligence.com/wire/#wire-055 The Saudi Food and Drug Authority and the Saudi National Institute of Health launched five initiatives at SFDA headquarters in Riyadh on 7 October, led by SFDA CEO Dr Hisham Aljadhey and Saudi NIH CEO Prof Fars Alanazi. The initiatives are a clinical trials agreement reference model, a guideline for establishing clinical trial units, a profile of hospitals and research centres specialised in clinical trials, a clinical trials reliance pathway, and the RAID pathway to support registration of innovative investigational medicines. Their stated aims are to strengthen trial infrastructure, speed up trials and accelerate development of new medicines to international standards. Why it matters. Standard contracts, defined trial units and a reliance pathway target the steps that decide how quickly a sponsor can open a Saudi site. Linking that infrastructure to a registration route for investigational medicines connects research activity directly to market access. Clinical Saudi Arabia 2026-10-07 https://www.a7iintelligence.com/wire/#wire-078 https://www.a7iintelligence.com/wire/#wire-078 The Ministry of Health and Prevention (MoHAP) has started implementing a resolution that sets two-phase caps per 100g on sodium, total sugars and bread fat across ten packaged food categories, among them bread, sweetened milk drinks, flavoured yoghurt and laban, salty snacks and processed cheese. First-phase windows of nine and 27 months lead to final limits by 31 December 2030, and fines range from AED 5,000 to AED 500,000. Why it matters. The caps move UAE food policy from strategy to enforceable product limits, with a clear reformulation timetable to 2030. Alongside the sugar-density excise on sweetened drinks in force since January 2026, they give food and drink makers aligned incentives to cut salt, sugar and fat. Regulation UAE 2026-10-06 https://www.a7iintelligence.com/wire/#wire-076 https://www.a7iintelligence.com/wire/#wire-076 Minister of Public Health Mansoor bin Ebrahim Al Mahmoud addressed the first meeting of Qatar's National Committee for Health Research Ethics on 5 October, calling for full compliance with ethical and legal standards in health research. The committee was created under Cabinet Decision No. 13 of 2026, and its powers include licensing research institutions and review committees, overseeing clinical trials, and issuing and renewing biobank licences. Its 13 member bodies include the Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar University, the Qatar Research, Development and Innovation Council and the Qatar Precision Health Institute. Why it matters. A single national body for research ethics, trial oversight and biobank licensing gives sponsors one clear governance route in Qatar, supporting the country's ambitions in clinical research and genomics. Regulation Qatar 2026-10-05 https://www.a7iintelligence.com/wire/#wire-060 https://www.a7iintelligence.com/wire/#wire-060 KAUST researchers, working with the University of Oxford, have developed a blood-based electronic sensor that detects three forms of alpha-synuclein, a protein closely linked to Parkinson's disease, in a study published in Science Advances. The method isolates small packages released by nerve cells into the bloodstream, then reads their protein contents with an organic electrochemical transistor, measuring all three forms within 40 minutes. In a blinded evaluation of 57 participants from the Oxford Discovery cohort, including people with isolated REM sleep behaviour disorder, it told disease-associated profiles apart from healthy controls with 90.9 percent accuracy. Why it matters. More than 95 percent of alpha-synuclein in blood comes from red blood cells, so isolating the nerve-derived fraction is what makes a brain signal readable from a blood sample. Measuring three forms together points toward earlier detection of neurodegeneration from a routine draw. Science Saudi Arabia 2026-10-04 https://www.a7iintelligence.com/wire/#wire-061 https://www.a7iintelligence.com/wire/#wire-061 The SFDA approved the registration of Jascayd (nerandomilast) for adults with idiopathic pulmonary fibrosis, a rare, progressive lung disease. The medicine is a phosphodiesterase 4 inhibitor that preferentially inhibits the PDE4B subtype, and it had previously received SFDA Orphan Drug designation. The SFDA cited the Phase 3 FIBRONEER-IPF trial of 1,177 patients over 52 weeks, in which lung function measured as forced vital capacity declined less on both doses than on placebo. Why it matters. The approval adds a new mechanism of action for a progressive orphan lung disease. It also shows an SFDA Orphan Drug designation converting into a full registration. Regulation Saudi Arabia 2026-10-03 https://www.a7iintelligence.com/wire/#wire-062 https://www.a7iintelligence.com/wire/#wire-062 The Department of Health Abu Dhabi announced on 2 October that the Abu Dhabi Future Health Summit 2026 will run from 20 to 22 October under the theme To Sense is to Predict, covering AI, genomics, diagnostics and health data for prediction and prevention. The organiser expects more than 175 exhibitors and attendees from about 100 countries, with speakers including AstraZeneca CEO Pascal Soriot and Isomorphic Labs President Max Jaderberg, and a forum track on investment in life sciences. Founding partners are PureHealth, M42, the Institute for Healthier Living Abu Dhabi and Mubadala Bio, and M42 said on 12 October it will use the summit for announcements on growth and collaborations. Why it matters. An investment track alongside longevity and precision health makes the summit a deal venue as well as a policy stage. Founding partners spanning care delivery, genomics and local medicines production give visiting companies direct commercial counterparts. Opportunity UAE 2026-10-02 https://www.a7iintelligence.com/wire/#wire-079 https://www.a7iintelligence.com/wire/#wire-079 The Saudi Food and Drug Authority (SFDA) and the National Nutrition Committee released the Food Classification Model guidance on 30 September 2026. The guidance sets out a nutrient profiling model and is framed as the basis for future rules on food advertising and on health and nutrition claims. Why it matters. The model gives the SFDA a single yardstick for its coming rules on food advertising and on health and nutrition claims. Releasing it first gives food brands time to benchmark their portfolios against it. Regulation Saudi Arabia 2026-09-30 https://www.a7iintelligence.com/wire/#wire-077 https://www.a7iintelligence.com/wire/#wire-077 Kuwait's Ministry of Health closed Duchenne Muscular Dystrophy Awareness Month on 30 September at the New Maternity Hospital, setting out an integrated system of prevention, early diagnosis, treatment and access to advanced gene therapies. The Kuwait Medical Genetics Centre has joined the hospital's departments to strengthen continuity of care. Officials reported that cooperation between the centre and the hospital's assisted reproduction unit has brought new cases among families with no prior genetic history down to about one a year, against an estimated five to seven implied by global incidence. Why it matters. Placing clinical genetics inside the maternity hospital connects carrier detection, reproductive options and paediatric care in one pathway, the foundation a health system needs to deploy gene therapies well. Clinical Kuwait 2026-09-30 https://www.a7iintelligence.com/wire/#wire-064 https://www.a7iintelligence.com/wire/#wire-064 A New York University Abu Dhabi team led by biology professor Kirsten Sadler Edepli, working with the university's Centre for Genomics and Systems Biology, published findings in EMBO Reports, as WAM reported on 29 September. Using a zebrafish model of liver cancer, the team found that activating a single cancer-causing gene pushed cells into different types of senescence: some entered permanent arrest while others regained the ability to divide. A senolytic compound cleared some precancerous cells and left others unaffected. Why it matters. Senolytics are one of the most closely watched drug classes in longevity and cancer medicine. Showing that the type of senescence shapes both tumour risk and drug response points to more precise targeting, and the work comes from an Abu Dhabi genomics centre. Science UAE 2026-09-29 https://www.a7iintelligence.com/wire/#wire-063 https://www.a7iintelligence.com/wire/#wire-063 The SFDA took enforcement action against websites and online accounts marketing unregistered peptide products, and started legal proceedings against the store owners for referral to the Public Prosecution. The authority said the products had not met pharmaceutical supply-chain, transport and storage requirements, while the platforms presented them as tested and officially approved. Article 34 of the Law of Pharmaceutical and Herbal Establishments and Preparations requires pharmaceutical products to be registered, with penalties reaching SAR 5 million, five years' imprisonment, or both. Why it matters. Peptides are widely marketed through longevity, aesthetics and wellness channels. By treating them as pharmaceutical products under the pharmaceutical establishments law, the SFDA confirms registration as the route to the Saudi market. Regulation Saudi Arabia 2026-09-29 https://www.a7iintelligence.com/wire/#wire-066 https://www.a7iintelligence.com/wire/#wire-066 Minister of Health and Prevention Ahmed bin Ali Al Sayegh led a delegation including Emirates Health Services and the Department of Health Abu Dhabi to leading US institutions on the sidelines of the 81st UN General Assembly, WAM reported on 27 September. Talks with Dana-Farber Cancer Institute covered an early cancer detection pathway using genomic testing, while meetings with Boston Children's Hospital, Mass General Brigham, NewYork-Presbyterian and Mount Sinai covered rare paediatric diseases, gene therapy, immunotherapy and digital health. Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Emirates Drug Establishment, joined a U.S.-U.A.E. Business Council meeting on expanding healthcare cooperation. Why it matters. Genomic early detection and rare disease care are where the UAE's population genome data meets clinical demand. The federal drug regulator's chairman at the business council table links clinical partnerships to market access. Partnership UAE 2026-09-27 https://www.a7iintelligence.com/wire/#wire-065 https://www.a7iintelligence.com/wire/#wire-065 Sheikh Hamdan bin Mohammed, Crown Prince of Dubai, approved the strategy and operating budget of the Dubai Longevity Authority after its inaugural board meeting on 27 September, moving the authority from establishment into implementation. The strategy targets annual growth of around 31% and a contribution of more than Dh35bn to Dubai's economy over the next decade. Priorities include an activity-based licensing framework, minimum standards and enforcement, and a Minimum Viable Product programme in which selected companies test and scale under regulatory supervision. Why it matters. Dubai now has a funded regulator with a published economic target for longevity, wellness and advanced health. Activity-based licensing and a supervised testing programme give longevity products and services a defined route to licensed market activity. Regulation UAE 2026-09-27 https://www.a7iintelligence.com/wire/#wire-067 https://www.a7iintelligence.com/wire/#wire-067 The Department of Health Abu Dhabi announced on 22 September its inaugural health and life sciences mission to China, running from 21 to 30 September across Shanghai, Shenzhen and Beijing and led by Undersecretary Dr Noura Khamis Al Ghaithi. The delegation includes Cleveland Clinic Abu Dhabi, PureHealth, the Abu Dhabi Investment Office, Mohamed bin Zayed University of Artificial Intelligence and L'IMAD. Priority areas are robotics, medical technology and AI; precision oncology and advanced diagnostics; drug development and clinical trials; and regulatory excellence and traditional medicine. Why it matters. Travelling with the regulator, the investment office and an AI university together presents Chinese companies with approvals, capital and data in one package. The mission opens a China corridor alongside the United States partnerships Abu Dhabi signed at BIO 2026. Global expansion UAE 2026-09-22 https://www.a7iintelligence.com/wire/#wire-033 https://www.a7iintelligence.com/wire/#wire-033 Across A7i's capital, infrastructure and clinical datasets the inward build is well established: operating biologics plants, WHO Maturity Level 4 regulation, population genomics at scale and frontier therapies reaching patients early. Outbound, A7i records two completed acquisitions in Britain, one Gulf-developed product with foreign customers and a state manufacturer operating on three continents. Why it matters. Every producer economy licenses technology in before it sells technology out, and the Gulf is three years into a programme designed to run for twenty. The outbound record is the measure worth watching from here, because it is the one that will show the inward build working. Global expansion GCC 2026-09-22 https://www.a7iintelligence.com/wire/#wire-001 https://www.a7iintelligence.com/wire/#wire-001 The fourth Riyadh Global Medical Biotechnology Summit concluded on 17 September with more than 40 agreements, initiatives and announcements. Asharq Al-Awsat reported the aggregate value at over SAR5bn, while the organiser's own release put it at SAR5.5bn. The event drew delegations from more than 57 countries and a Life Sciences Innovation Forum reported $120m of investor interest across five specialised funds. Why it matters. Announced aggregate value records intent at scale. Itemising the forty agreements is what will turn a headline figure into a trackable pipeline. Capital Saudi Arabia 2026-09-17 Asharq Al-Awsat https://www.a7iintelligence.com/wire/#wire-002 https://www.a7iintelligence.com/wire/#wire-002 PureHealth has taken over selected laboratory operations from Unilabs Limited, including hub laboratories at Euston and Cavendish Square in London and a network of licensed laboratories across the country. The operations cover pathology, histopathology, blood sciences, microbiology and specialist diagnostics, serving more than 50 hospitals operated by Circle Health Group and more than 90 external clients. Why it matters. The Gulf's outbound life-science record has been built on hospital services. This extends it into laboratory diagnostics, which is a capability rather than a footprint. Global expansion UAE 2026-09-13 Gulf News https://www.a7iintelligence.com/wire/#wire-003 https://www.a7iintelligence.com/wire/#wire-003 Gulf Pharmaceutical Industries, listed in Abu Dhabi and manufacturing in Ras Al Khaimah, reported half-year results citing improved profitability, revenue growth and a strengthened balance sheet. Why it matters. Julphar stands out among Gulf-founded pharmaceutical manufacturers for a public reporting record stretching back decades. Its results give the sector a recurring, hard financial benchmark in a field largely reported through announcements. Company UAE 2026-08-13 Julphar https://www.a7iintelligence.com/wire/#wire-035 https://www.a7iintelligence.com/wire/#wire-035 The Saudi Food and Drug Authority prohibited cosmetic products packaged to resemble injectables and mandated accompanying warning statements. The rule takes effect on 1 January 2027. Why it matters. Cosmetic products sold in syringe-shaped containers borrow the visual authority of a medical procedure without the regulatory burden of one. The SFDA has addressed this directly by regulating the packaging rather than waiting to litigate the claim. Regulation Saudi Arabia 2026-08-11 Saudi Food and Drug Authority https://www.a7iintelligence.com/wire/#wire-004 https://www.a7iintelligence.com/wire/#wire-004 Sidra Medicine administered a Novartis gene therapy to Qatar's first patient with spinal muscular atrophy. Reporting describes Qatar as the third country worldwide to administer the therapy. Why it matters. The therapy is Swiss. What is Qatari is the capability to deliver it, which requires a centre able to handle an advanced therapy and a payer willing to fund one. Clinical Qatar 2026-07-29 HealthCare MEA https://www.a7iintelligence.com/wire/#wire-005 https://www.a7iintelligence.com/wire/#wire-005 Invest Qatar has set out a biotechnology proposition built on Qatar Foundation, the Qatar Biomedical Research Institute, Sidra Medicine and Weill Cornell Medicine-Qatar, with precision medicine and genomics as the focus. Why it matters. Qatar has chosen depth over breadth. Where Saudi Arabia leads on manufacturing scale and the UAE on data scale, Qatar leads on concentration: its institutions sit within a single foundation rather than across competing ministries. Opportunity Qatar 2026-07-28 Gulf Times https://www.a7iintelligence.com/wire/#wire-006 https://www.a7iintelligence.com/wire/#wire-006 Seha Invest, a Saudi healthcare finance firm, signed a $500m partnership with Boston-based Y-Innovations at the London Stock Exchange, announced at the BMG Economic Forum on 8 July. The stated scope covers bringing international biotechnology companies into the Kingdom, technology transfer and localised vaccine production. Why it matters. Announced partnership value, with deployment as the next figure to track. The structure is notable because it routes capital around the state contract manufacturer rather than through it. Capital Saudi Arabia 2026-07-08 Arab News https://www.a7iintelligence.com/wire/#wire-007 https://www.a7iintelligence.com/wire/#wire-007 At BIO in San Diego the Ministry of Health announced Launch in Saudi, a programme intended to speed access to health innovations and advanced therapies, alongside a clinical-trials investment roundtable with global contract research and pharmaceutical representatives. Why it matters. Access programmes prove themselves in delivery. The measure that matters is how many advanced therapies reach Saudi patients through it, and how fast. Regulation Saudi Arabia 2026-07-06 Arab News https://www.a7iintelligence.com/wire/#wire-008 https://www.a7iintelligence.com/wire/#wire-008 Version 1.0 of the SFDA biosimilar guideline was issued on 10 June 2026 and took effect on 10 July 2026, setting development and approval requirements for the class. Why it matters. Biosimilars are where localisation economics work best, because the molecule is established and the competitive variable is manufacturing cost. A clear national guideline is the precondition for that. Regulation Saudi Arabia 2026-07-01 Bird & Bird https://www.a7iintelligence.com/wire/#wire-009 https://www.a7iintelligence.com/wire/#wire-009 IROS, part of M42, the Department of Health Abu Dhabi and Halia Therapeutics are using Emirati Genome Programme data to identify APOE4 carriers before symptoms appear, then trialling an investigational therapy in that cohort. Why it matters. This is the first published instance of the Emirati genomic dataset being used to construct a trial cohort rather than to describe a population. The dataset and the recruitment strategy are Emirati; the therapeutic asset is American. Clinical UAE 2026-06-29 PharmaTimes https://www.a7iintelligence.com/wire/#wire-010 https://www.a7iintelligence.com/wire/#wire-010 The Abu Dhabi Biobank signed BioTwin to run AI virtual human twin models against its genomic and clinical data, beginning with multi-cancer screening. Why it matters. The consideration here is data access rather than capital, so data itself is the currency of the deal. It also makes the biobank's retained rights the term worth watching. Partnership UAE 2026-06-26 Gulf News https://www.a7iintelligence.com/wire/#wire-011 https://www.a7iintelligence.com/wire/#wire-011 Biosphere Labs opened at Masdar City with M42 and Attentive Science, described as the first commercially scaled shared laboratory in the GCC. Why it matters. Laboratory capital cost is the largest hurdle for early-stage biotechnology in the region. Shared facilities address it directly, and this is the first in the GCC at commercial scale. Infrastructure UAE 2026-06-25 Gulf News https://www.a7iintelligence.com/wire/#wire-015 https://www.a7iintelligence.com/wire/#wire-015 The Department of Health Abu Dhabi and Biocom California, which represents more than 1,800 life-sciences companies, established a formal corridor between the two ecosystems. Why it matters. Industry-association corridors create their value through the deal flow that follows, which is what A7i will track here. Partnership UAE 2026-06-24 BioProcess International https://www.a7iintelligence.com/wire/#wire-014 https://www.a7iintelligence.com/wire/#wire-014 Announced at BIO 2026, the hub is intended to route therapies from Abu Dhabi into regional markets. Why it matters. A distribution hub is a routing role rather than a production one. It is also the step that most often precedes local packaging and manufacture. Infrastructure UAE 2026-06-24 World Pharma Today https://www.a7iintelligence.com/wire/#wire-013 https://www.a7iintelligence.com/wire/#wire-013 The Department of Health Abu Dhabi and M42 announced a CRISPR gene-editing and precision medicine hub with Mammoth Biosciences at BIO 2026, using Emirati Genome Programme data to develop therapies for inherited disease, with stated intent to manufacture advanced therapies in Abu Dhabi. Why it matters. Sequencing and discovery partnerships have been signed repeatedly across the region. Manufacturing intent is the part of this one that would be new. Partnership UAE 2026-06-24 Gulf News https://www.a7iintelligence.com/wire/#wire-012 https://www.a7iintelligence.com/wire/#wire-012 Mubadala Bio will produce endocrinology, nephrology and oncology biologics at its DiabTec facility under a licensing and supply agreement with Argentina's Biosidus. Why it matters. The counterparty is Argentine rather than American or European, which is distinctive and suggests the selection criterion was willingness to transfer technology rather than brand. Manufacturing UAE 2026-06-24 Zawya https://www.a7iintelligence.com/wire/#wire-016 https://www.a7iintelligence.com/wire/#wire-016 The two companies signed at BIO 2026 an agreement covering commercialisation and distribution of Multikine in Saudi Arabia, with a local representative handling SFDA filings and an option to expand across the GCC. Why it matters. This is a distribution agreement. It is recorded because the pre-negotiated GCC expansion clause is becoming a standard feature of Saudi entry agreements. Partnership Saudi Arabia 2026-06-12 Business Wire https://www.a7iintelligence.com/wire/#wire-017 https://www.a7iintelligence.com/wire/#wire-017 The Emirates Drug Establishment approved AstraZeneca's ESR1-targeted breast cancer therapy shortly after Saudi clearance, and ahead of a United States advisory committee recommendation. Why it matters. Gulf regulators are increasingly clearing frontier oncology before or alongside Western markets. Each early clearance strengthens the region's standing as a first-launch market. Regulation UAE 2026-06-11 The National https://www.a7iintelligence.com/wire/#wire-034 https://www.a7iintelligence.com/wire/#wire-034 Law No. 17 of 2026 established the Dubai Longevity Authority, chaired by Helal Almarri under the Crown Prince. Its published mandate spans research and development, clinical trials, manufacturing and clinic operation for longevity therapies. It is the first dedicated regulator for the category in any jurisdiction. Why it matters. Longevity medicine elsewhere is practised across existing regulators: a clinic licence here, a device approval there. Dubai has made one authority responsible for the category itself. That decides where the rulebook gets written. Regulation UAE 2026-06-10 Gulf News https://www.a7iintelligence.com/wire/#wire-018 https://www.a7iintelligence.com/wire/#wire-018 M42 and ADQ's pharmaceutical platform Arcera announced a partnership covering biopharmaceutical localisation and next-generation life sciences in the emirate. Why it matters. Abu Dhabi now has two sovereign-built life-science platforms, Mubadala Bio and Arcera, under different owners. Whether they consolidate or compete is the structural development to watch. Partnership UAE 2026-06-03 TradingView carrying Zawya https://www.a7iintelligence.com/wire/#wire-043 https://www.a7iintelligence.com/wire/#wire-043 Abu Dhabi Biobank, jointly led by the Department of Health Abu Dhabi and M42, partnered with Human Life CORD Japan to build a localised GMP manufacturing pathway for umbilical cord mesenchymal stem cell therapies. Stated target applications include age-related frailty and musculoskeletal degeneration. Why it matters. The Gulf already administers cell therapies. A domestic GMP pathway for UC-MSC would be the first local production of a cell therapy product in the UAE, taking the UAE from delivery to manufacture. Manufacturing UAE 2026-05-05 Abu Dhabi Media Office https://www.a7iintelligence.com/wire/#wire-039 https://www.a7iintelligence.com/wire/#wire-039 The Ministry of Health launched a national inspection campaign covering hair transplant providers across the Kingdom. Why it matters. Hair restoration is one of the largest aesthetic procedure volumes in the Gulf. A national campaign signals the ministry has made practice standards a priority. Regulation Saudi Arabia 2026-04-30 Saudi Ministry of Health https://www.a7iintelligence.com/wire/#wire-020 https://www.a7iintelligence.com/wire/#wire-020 The Omani Ministry of Health set a deadline of six months from 22 April 2026 for all imported medical devices, including diagnostic, therapeutic and surgical equipment. Shipments from non-compliant firms are to be suspended at entry points after that date. Why it matters. Oman is the smallest of the six device markets and is now formalising registration. A hard import deadline makes registration the clear route to market. Regulation Oman 2026-04-23 Lexis Middle East https://www.a7iintelligence.com/wire/#wire-021 https://www.a7iintelligence.com/wire/#wire-021 The EDE registered orforglipron, an oral alternative to injectable weight-management therapies, reported as the second registration worldwide. Why it matters. Metabolic disease prevalence in the Gulf is high and payers are willing. That combination is why the region keeps appearing near the front of the launch sequence for this class. Regulation UAE 2026-04-07 HealthCare MEA